RIPK1 and central nervous system cancer: Similar conclusions were drawn by Zhou et al. [58], who studied the effects of emodin treatment in the U251 glioma cells by targeting the TNF-α/receptor-interacting serine/threonine-protein kinase 1/3 (RIP1/RIP3) signaling pathway.